Cargando…

Biomarkers of Everolimus Sensitivity in Hormone Receptor-Positive Breast Cancer

Activation of the mammalian target of rapamycin (mTOR) signaling pathway is an important mechanism of resistance to endocrine therapy in breast cancer. Everolimus, an mTOR inhibitor, has been shown to increase the efficacy of endocrine therapy and overcome resistance to endocrine therapies. Clinical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yi, Zongbi, Ma, Fei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Breast Cancer Society 2017
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5743990/ https://www.ncbi.nlm.nih.gov/pubmed/29285035 http://dx.doi.org/10.4048/jbc.2017.20.4.321

Ejemplares similares

Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study
por: Yi, Zongbi, et al.
Publicado: (2019)

Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers
por: Yi, Zongbi, et al.
Publicado: (2020)

Statin use in patients with hormone receptor‐positive metastatic breast cancer treated with everolimus and exemestane
por: Lee, Kyoungmin, et al.
Publicado: (2022)

RETRACTION: Challenges of Combined Everolimus/Endocrine Therapy in Hormone Receptor-Positive Metastatic Breast Cancer
por: Porta, Camillo
Publicado: (2014)

Everolimus and exemestane in long survival hormone receptor positive male breast cancer: case report
por: Ballatore, Z., et al.
Publicado: (2016)

New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus
por: Paplomata, Elisavet, et al.
Publicado: (2013)

Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study
por: Schettini, Francesco, et al.
Publicado: (2020)

Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib
por: Dhakal, Ajay, et al.
Publicado: (2020)

Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer
por: Freelander, Allegra, et al.
Publicado: (2021)

Antibody-drug conjugates in HER2-positive breast cancer
por: Li, Lixi, et al.
Publicado: (2022)

Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial
por: Peterson, Mary E.
Publicado: (2013)

Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
por: Rozenblit, Mariya, et al.
Publicado: (2021)

Efficacy and safety of low-dose everolimus combined with endocrine drugs for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer
por: Zhang, Hui-Qiang, et al.
Publicado: (2021)

Long-Term Results with Everolimus in Advanced Hormone Receptor Positive Breast Cancer in a Multicenter National Real-World Observational Study
por: François-Martin, Hélène, et al.
Publicado: (2023)

Everolimus in the Treatment of Metastatic Breast Cancer
por: Royce, Melanie E, et al.
Publicado: (2015)

Early Changes of the Standardized Uptake Values (SUV(max)) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer
por: Sirico, Marianna, et al.
Publicado: (2020)

Alpelisib Efficacy in Hormone Receptor-Positive HER2-Negative PIK3CA-Mutant Advanced Breast Cancer Post-Everolimus Treatment
por: Raphael, Ari, et al.
Publicado: (2022)

Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2
por: Noguchi, Shinzaburo, et al.
Publicado: (2013)

ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer
por: Brett, Jamie O., et al.
Publicado: (2021)

Cannabinoids and Hormone Receptor-Positive Breast Cancer Treatment
por: Dobovišek, Luka, et al.
Publicado: (2020)

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2
por: Rugo, H. S., et al.
Publicado: (2014)

A Case of Disease Improvement after Treatment with Everolimus plus Exemestane in a Patient with Hormone Receptor-Positive Metastatic Breast Cancer with Bone Metastases
por: Beck, J. Thaddeus, et al.
Publicado: (2015)

Endocrine therapy combined with targeted therapy in hormone receptor-positive metastatic breast cancer
por: Bian, Li, et al.
Publicado: (2020)

Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study
por: Kourlaba, Georgia, et al.
Publicado: (2015)

Combination Therapies in Advanced, Hormone Receptor–Positive Breast Cancer
por: Olson, Emily
Publicado: (2018)

Phase II randomized trial of a non-steroidal mouth wash for prevention and treatment of stomatitis in women with hormone receptor positive breast cancer treated with everolimus
por: Peddi, Parvin F., et al.
Publicado: (2020)

A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer
por: Vaklavas, Christos, et al.
Publicado: (2023)

Estrogen receptor positive breast cancers have patient specific hormone sensitivities and rely on progesterone receptor
por: Scabia, Valentina, et al.
Publicado: (2022)

Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications
por: Vernieri, Claudio, et al.
Publicado: (2020)

Efficacy of everolimus‐based therapy in advanced triple‐positive breast cancer: Experience from three cancer centers in China
por: Tan, Yujing, et al.
Publicado: (2023)

Considerations for payers in managing hormone receptor-positive advanced breast cancer
por: Chitre, Mona, et al.
Publicado: (2014)

Treating Elderly Patients With Hormone Receptor–Positive Advanced Breast Cancer
por: Riseberg, David
Publicado: (2015)

Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
por: D’Souza, Anishka, et al.
Publicado: (2018)

PI3Kinase Inhibition in Hormone Receptor-Positive Breast Cancer
por: Dhakal, Ajay, et al.
Publicado: (2021)

Genetics, Treatment, and New Technologies of Hormone Receptor-Positive Breast Cancer
por: Sebastian, William, et al.
Publicado: (2023)

XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease
por: Schmid, Peter, et al.
Publicado: (2023)

Safety, Efficacy, and Patient Acceptability of Everolimus in the Treatment of Breast Cancer
por: Lousberg, Laurence, et al.
Publicado: (2017)

Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer
por: Migliaccio, Ilenia, et al.
Publicado: (2021)

Clinical Predictive Factors for the Efficacy of Everolimus in Patients With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: A Multicenter Retrospective Cohort Study in Japan
por: Kikawa, Yuichiro, et al.
Publicado: (2019)

The Immunology of Hormone Receptor Positive Breast Cancer
por: Goldberg, Jonathan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_15f3jd162s3lm9h0i73q8lsuk2